Insider buying last 90 days
No open-market insider purchases were filed for TAK in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TAK insider filing, plotted on the chart in Gekko.Open TAK in Gekko
Takeda Pharmaceutical (TAK) Stock Analysis & Forecast
$18.91−0.14 (−0.7%)
Close on Sep 18, 2026. Page updated Sep 19, 9:19 pm ET.
Gekko Brief
AI summaryTakeda closes at $18.91, down 0.7% on the day but sitting above both its 50-day ($17.67) and 200-day ($16.95) moving averages, with the shorter average above the longer one. The stock trades near its 52-week high of $19.10, up 21% over three months and 25.3% over the past year. The GekkoIndex reads 47.5, placing it in the Neutral zone, down 7.8 points over five days. Against this, Gekko Fair Value stands at $24.68, leaving price 23.4% below that level.
News this week centers on regulatory and partnership progress. Takeda and Dr. Reddy's Laboratories announced an exclusive collaboration to promote and distribute Takeda's QDENGA dengue vaccine in India's private pediatric and adult market, with availability expected in early 2027. Separately, the U.S. FDA accepted Takeda's New Drug Application under Priority Review for zasocitinib (TAK-279) in moderate-to-severe plaque psoriasis, setting a target action date in the first quarter of 2027. Additional coverage included a financial comparison with Teva Pharmaceutical and a transcript from Takeda's appearance at the Morgan Stanley 24th Annual Global Healthcare Conference.
Takeda's next earnings report is scheduled for 29 October 2026, before the open, 39 days away and outside a typical 20-trading-day holding window; the prior quarter saw a $0.48 actual versus $0.55 estimate, with a 3.2% reaction. Seasonality over the next 20 trading days has averaged -8.7% across 5 years, with 0 of those years positive. Consensus from covering analysts carries a $22.26 target, implying 17.7% upside from current levels.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $18.91200-day averageGekko Fair Value $24.68
Key stats
- Market cap
- $60.17B
- P/E ratio
- —
- Forward P/E
- 11.2
- EPS, TTM
- −$0.35
- Revenue, TTM
- $4.62T
- Profit margin
- -3.5%
- Dividend yield
- 3.31%
- Beta
- 0.10
- Volume
- 2.48M avg 2.09M
- 1-year return
- +25.3%
- Typical daily move
- ±1.6%
- Typical 20-day move
- ±3.9%
- 50-day average
- $17.67
- 200-day average
- $16.95
- Next earnings
- Oct 29 before open
- Shares outstanding
- 3.19B
Takeda Pharmaceutical swing-trade checklist
Takeda Pharmaceutical scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $18.91 is above the 50-day ($17.67) and 200-day ($16.95) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
47.5, Neutral
Reading 47.5 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
23.4% below
Price is 23.4% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 39 days
Next report Oct 29, 2026, 39 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−8.7% on average
From this point in the calendar, the next 20 trading days averaged −8.7% over 5 years, rising in 0 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Takeda Pharmaceutical stock chart and price history
Takeda Pharmaceutical closed at $18.91 on Sep 18, 2026, +25.3% over the past year, inside a 52-week range of $12.99 to $19.10.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +3.1%
- 3 months
- +21.0%
- 6 months
- +4.4%
- 1 year
- +25.3%
The full TAK chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TAK in Gekko
Follow Takeda Pharmaceutical through every session
Put TAK on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TAK in GekkoFree for 7 days. No credit card required.
About Takeda Pharmaceutical
Takeda Pharmaceutical works across the full life cycle of medicines, from early discovery through development, manufacturing, sale and licensing to other firms. It sells treatments aimed at digestive conditions, rare diseases, blood-plasma therapies, cancer and neurological disorders, reaching patients in Japan, the United States, Europe, Canada, Latin America, Russia and other markets in Asia and beyond. Its products are sold under a long list of brand names, including Entyvio, Takecab, Dexilant, Advate, Adcetris, Vyvanse and Trintellix, among many others.
Beyond its own pipeline, Takeda builds its business through a network of outside agreements. It licenses products out to companies such as Neurocrine Biosciences, and it brings in research or licensed compounds through deals with groups like MD Anderson Cancer Center, Arrowhead Pharmaceuticals, Ovid Therapeutics and Evox Therapeutics. It also runs research partnerships with firms including Crescendo Biologics, Poseida Therapeutics, Selecta Biosciences, Skyhawk Therapeutics and Evotec, among several others.
The company was founded in 1781 and is headquartered in Tokyo, Japan. Its shares trade under the ticker TAK.
- Sector
- Health technology
- Website
- takeda.com
Takeda Pharmaceutical GekkoIndex: the smart money zone
Takeda Pharmaceutical’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47.5, in the Neutral zone, down 7.8 points over five sessions.
47.5Neutral
Down 7.8 points over five sessions.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 44 | +0.9% | +1.0% | ||
| Accumulation | 203 | −0.2% | +0.1% | ||
| Neutral (current zone) | 338 | +0.5% | +1.5% | ||
| Distribution | 30 | +0.2% | +4.5% | ||
| Selling | 0 | Not available | |||
Average TAK share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the TAK price, zone by zone.Track TAK in Gekko
Is Takeda Pharmaceutical stock overvalued? Gekko Fair Value
Takeda Pharmaceutical trades 23.4% below Gekko Fair Value of $24.68, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Takeda Pharmaceutical shares are worth, recalculated every trading day.
$24.68
Gekko Fair Value, Sep 19, 2026
23.4% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open TAK in Gekko
Takeda Pharmaceutical insider and Congress trading
No open-market insider purchases were filed for Takeda Pharmaceutical, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TAK were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TAK, plotted on the chart in Gekko.Open TAK in Gekko
Takeda Pharmaceutical earnings: next date and track record
Takeda Pharmaceutical reports on Oct 29, 2026, before the open (39 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected before the open, 39 days away
- EPS estimate
- $0.15
- Revenue estimate
- $7.31B
3 of 8reports beat the EPS estimate
±2.3%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jan 29, 2026 AI summary
- What they said
- The third quarter FY'25 earnings call for Takeda covers strong underlying fundamentals and cost discipline, progress on late-stage pipeline (ove p orexton, rusfertide, zasocitinib) with regulatory filings and near-term launches over the next 18 months, and ongoing transitions under CEO-elect Julie Kim. The company notes impact from VYVANSE generic erosion but shows improving quarterly momentum, robust cash flow, and a plan to provide fiscal 2026 guidance in May. The Q&A touches MFN/U.S. policy considerations, organizational changes, ENTRVIO performance and IRA price negotiations, TAKHZYRO dynamics amid competition, PDT and immunoglobulin outlook, and Zasocitinib data timing and regulatory pathway. Overall tone blends optimism about new launches and pipeline with cautious commentary on policy headwinds, cost pressures from launches, and near-term guidance timing.
- Guidance
- No formal raised or lowered guidance announced during Q3 remarks. Guidance for fiscal year 2026 will be provided by Julie Kim in May. The company reaffirmed the path to mid-term objectives and highlighted expected contribution from new products, with full-year projections (e.g., ENTYVIO growth around 6% for the year) and ongoing cost discipline. They expect to meet PDT and immunoglobulin forecasts, while R&D and launch costs will rise due to new assets.
- Risks flagged
- MFN/U.S. policy developments and potential price controls (IRA), changes in U.S. Medicare/Part D-related dynamics, LOE (loss of exclusivity) impact, competition from new entrants (e.g., DAWNZERA), U.S. formulary coverage and payer dynamics, currency headwinds, and execution risk around major launches. Also risks around timing of Zasocitinib data readouts and regulatory timelines.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jan 29, 2026 | $0.48 est $0.55 | $7.73B est $7.54B | +3.2% |
| Oct 30, 2025 | $0.44 est $0.44 | $7.42B est $7.48B | −2.4% |
| Jul 30, 2025 | $0.52 est $0.47 | $7.64B est $7.95B | −4.2% |
| May 8, 2025 | −$0.23 est −$0.17 | — | −4.6% |
| Jan 30, 2025 | $0.05 est $0.63 | $7.28B est $7.06B | +0.6% |
| Oct 31, 2024 | $29.07 est $87.45 | $7.91B est $7.45B | +0.5% |
| Jul 31, 2024 | $0.19 est $0.12 | $7.52B est $6.98B | +1.5% |
| May 9, 2024 | −$0.01 est −$0.01 | $6.93B est $6.06B | +1.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Takeda Pharmaceutical stock forecast and analyst price targets
Analysts’ average 12-month price target for Takeda Pharmaceutical is $22.26, +17.7% from the last close, from 1 firm rating the stock in the last 90 days.
$22.26consensus 12-month target, +17.7% from the last close
Each firm’s latest rating in the last 90 days: 1 firm.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 14 | Bank of America Securities | $43.92 | +132.3% |
| Aug 13 | Bank of America Securities | $42.65 | +125.5% |
| Aug 6 | Bank of America Securities | — | — |
| Jul 30 | Bank of America Securities | $36.70 | +94.1% |
+1.5%average 20-day move after past Neutral readings
−8.7%average move over the next 20 trading days in the last 5 years
±1.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Takeda Pharmaceutical seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Takeda Pharmaceutical averaged −8.7% across the last 5 years, rising in 0 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.1% | 0 of 5 |
| Next 10 trading days | −4.6% | 0 of 5 |
| Next 15 trading days | −7.5% | 0 of 5 |
| Next 20 trading days | −8.7% | 0 of 5 |
| Next 30 trading days | −10.3% | 0 of 5 |
For scale, TAK’s typical 20-trading-day move in either direction is about 3.9%.
Takeda Pharmaceutical market cap and key statistics
Takeda Pharmaceutical’s market cap is $60.17B and revenue of $4.62T over the last twelve months.
Valuation
- Market cap
- $60.17B
- Forward P/E
- 11.2
- EPS, TTM
- −$0.35
- Gekko Fair Value
- $24.68
Trading
- Volume
- 2.48M
- Avg volume, 20 days
- 2.09M
- 52-week high
- $19.10
- 52-week low
- $12.99
- Shares outstanding
- 3.19B
Financials
- Revenue, TTM
- $4.62T
- Profit margin
- -3.5%
- Return on equity
- -2.3%
- Quarterly earnings growth, YoY
- −9.8%
Risk and income
- Beta
- 0.10
- Typical daily move
- ±1.6%
- Typical 20-day move
- ±3.9%
- Dividend yield
- 3.31%
Takeda Pharmaceutical stock news this week
Coverage of Takeda Pharmaceutical this week reads positive: 3 positive, 2 neutral and 0 negative headlines.
- India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in IndiaBradenton Herald, Sep 18
- Takeda and Dr. Reddy's Laboratories enter into exclusive collaboration to promote and distribute QDENGA in India's pediatric and adult private marketBig News Network.com, Sep 18
- Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health SystemsBusiness Wire, Sep 18
- Takeda Pharmaceutical (NYSE:TAK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Financial ContrastDefense World, Sep 16
- Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha, Sep 14
- U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment ExpectationsBusiness Wire, Sep 14
Takeda Pharmaceutical stock FAQ
What is Takeda Pharmaceutical’s market cap?
Takeda Pharmaceutical’s market cap is $60.17B at the Sep 18, 2026 close of $18.91, with 3.19B shares outstanding.
What is the Takeda Pharmaceutical stock forecast?
The consensus analyst 12-month price target for Takeda Pharmaceutical is $22.26, +17.7% from the last close. Of the 1 firm that rated the stock in the last 90 days, 1 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Takeda Pharmaceutical stock overvalued or undervalued?
On Gekko’s estimate Takeda Pharmaceutical is undervalued: the Sep 18, 2026 close of $18.91 is 23.4% below Gekko Fair Value of $24.68. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Takeda Pharmaceutical report earnings next?
Takeda Pharmaceutical is expected to report on Oct 29, 2026, before the market opens (39 days away). Analysts expect earnings of $0.15 per share on revenue of $7.31B. Takeda Pharmaceutical beat the earnings estimate in 3 of its last 8 reports, moving 2.3% on average across the report.
What is Takeda Pharmaceutical’s 52-week high and low?
Takeda Pharmaceutical’s 52-week high is $19.10 and its 52-week low is $12.99; it closed at $18.91 on Sep 18, 2026, +25.3% over the past year.
Is Takeda Pharmaceutical stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and earnings risk), 1 as mixed (gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Takeda Pharmaceutical the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.